No, I am saying we are sitting pretty with BP when competitors within BP start thinking that someone else will acquire Leronlimab and cut them out of profits. When the share price jumps on NO news they must be thinking, "someone knows something" so no, I don't think they mute us, I think they start wondering if now is the time to get LL.

Look, you well know what we have here; the potential for Leronlimab is off the charts, but this a double edged sword. They can either suppress it to keep it off the market or they can buy so others don't get it first. So Pfizer has taken a drug off the shelves for NASH, what if GSK buys Leronlimab and knocks them out of the market. Retribution because Pfizer just knocked GSK out of the market on RSV vaccine, but GSK stole Pfizer's lead vaccine specialist. This is a perfect dog eat dog world for LL.